Given limited information at market authorization, combined with the speed at which vaccination will take place, upcoming mass vaccination programs for COVID-19 will be associated with a significant spike in adverse event reporting. The pharma industry must plan its response to gathering data on the safety of both vaccines and medicines used with them in response to this unprecedented global campaign. Pharmacovigilance teams across all companies must be prepared. View Article here.
A Coming Tidal Wave: Predicting Impacts of the Pending COVID-19 Vaccination Campaign on Safety Reporting, Tracking, and Liability for the Entire Industry
Nov 17, 2020
Posted by Sidley Austin